Sumitomo Pharmaceuticals, along with its parent Sumitomo Chemical entered into merger agreement with Dainippon Pharmaceuticals. The new company formed would focus on diabetes, CNS disorders, immunology and allergies. The deal could be worth up to ¥227 B (US$2.2 B) to Dainippon Pharmaceuticals.